{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:02:42Z","timestamp":1786460562083,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n Objective:<\/jats:title>\n This systematic review will aim to evaluate the evidence on the cost-effectiveness of artemisinin-based combination therapies (ACTs) when used as a first-line treatment for malaria, providing evidence-based guidance for policymakers in resource-limited settings.<\/jats:p>\n <\/jats:sec>\n \n Introduction:<\/jats:title>\n \n ACTs have become the World Health Organization\u2019s recommended first-line treatment for uncomplicated\n Plasmodium falciparum<\/jats:italic>\n malaria due to their efficacy. Economic constraints in endemic regions necessitate the assessment of their cost-effectiveness.\n <\/jats:p>\n <\/jats:sec>\n \n Eligibility criteria:<\/jats:title>\n Studies will be eligible if they report on the cost-effectiveness or cost-utility of ACTs and non-ACT or different ACT dose regimens as first-line treatments for malaria among pediatric and adult populations.<\/jats:p>\n <\/jats:sec>\n \n Methodology:<\/jats:title>\n This review will follow the JBI methodology for systematic reviews of economic evidence. PubMed was used to conduct a preliminary search using MeSH terms such as malaria, artemisinin combination therapy, non-artemisinin combination therapy, and cost-effectiveness. This initial search strategy will be adapted to other academic and non-academic databases as well as gray literature. Two reviewers will independently screen records at the title\/abstract and full-text levels, with disagreements resolved by a third reviewer. Two reviewers will then conduct a methodological quality assessment and extract data in accordance with JBI guidelines. A summary and comparison of the included studies will be based on the JBI Dominance Ranking Matrix for economic evaluations. The measures of cost-effectiveness\/cost-utility will consist of the incremental cost-effectiveness ratio (ICER), the ICER per disability-adjusted life year averted, or the quality-adjusted life years gained. The GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach will be used to appraise the certainty of economic evidence.<\/jats:p>\n <\/jats:sec>\n \n PROSPERO registration ID:<\/jats:title>\n CRD420251058688.<\/jats:p>\n <\/jats:sec>","DOI":"10.11124\/jbies-25-00243","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:00:10Z","timestamp":1778490010000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of artemisinin-based combination therapies for first-line treatment of malaria among pediatric and adult populations: a systematic review protocol"],"prefix":"10.11124","author":[{"given":"Bindu","family":"MA","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, MS Ramaiah University of Applied Sciences, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spoorthi","family":"KR","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, MS Ramaiah University of Applied Sciences, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Jith","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, MS Ramaiah University of Applied Sciences, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-3765","authenticated-orcid":false,"given":"Saraswathy","family":"GR","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, MS Ramaiah University of Applied Sciences, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-8708","authenticated-orcid":false,"given":"Chandrasekhar","family":"Janakiram","sequence":"additional","affiliation":[{"name":"Department of Public Health Dentistry, Amrita School of Dentistry, Amrita Vishwa Vidyapeetham, Kochi, India"},{"name":"JBI Amrita Centre for Evidence-Based Oral Health, Amrita School of Dentistry, Amrita Vishwa Vidyapeetham, Amrita, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4486-632X","authenticated-orcid":false,"given":"Denny","family":"John","sequence":"additional","affiliation":[{"name":"Faculty of Life and Allied Health Sciences, MS Ramaiah University of Applied Sciences, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"3","key":"R1-20260515","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1053\/j.spid.2004.05.009","article-title":"Prevention and treatment of malaria in young African children","volume":"15","author":"Crawley","year":"2004","journal-title":"Semin Pediatr Infect Dis"},{"issue":"1","key":"R2-20260515","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1038\/s41467-023-39914-3","article-title":"Preventing antimalarial drug resistance with triple artemisinin-based combination therapies","volume":"14","author":"Nguyen","year":"2023","journal-title":"Nat Commun"},{"issue":"19","key":"R3-20260515","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.3390\/jcm13195680","article-title":"Global fight against malaria: goals and achievements 1900-2022","volume":"13","author":"Thellier","year":"2024","journal-title":"J Clin Med"},{"issue":"5","key":"R4-20260515","doi-asserted-by":"crossref","first-page":"e0285265","DOI":"10.1371\/journal.pone.0285265","article-title":"Pooled prevalence and risk factors of malaria among children aged 6-59 months in 13 sub-Saharan African countries: a multilevel analysis using recent malaria indicator surveys","volume":"18","author":"Chilot","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"R5-20260515","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1186\/s12889-024-19206-1","article-title":"Malaria in under-five children: prevalence and multi-factor analysis of high-risk African countries","volume":"24","author":"Mbishi","year":"2024","journal-title":"BMC Public Health"},{"issue":"12","key":"R6-20260515","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJMp1108322","article-title":"The threat of artemisinin-resistant malaria","volume":"365","author":"Dondorp","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"R7-20260515","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"R8-20260515","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12879-021-06018-6","article-title":"Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis","volume":"21","author":"Shibeshi","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R9-20260515","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijpddr.2020.11.006","article-title":"Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: a systematic review of clinical studies from two malaria endemic regions - India and sub-Saharan Africa","volume":"15","author":"Arya","year":"2021","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"7","key":"R10-20260515","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1179\/000349804225021514","article-title":"Efficacies of chloroquine, sulfadoxine-pyrimethamine and quinine in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan","volume":"98","author":"Adam","year":"2004","journal-title":"Ann Trop Med Parasitol"},{"issue":"9918","key":"R11-20260515","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(13)60024-0","article-title":"Malaria","volume":"383","author":"White","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"R13-20260515","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1371\/journal.pmed.0030373","article-title":"Cost-effectiveness study of three antimalarial drug combinations in Tanzania","volume":"3","author":"Wiseman","year":"2006","journal-title":"PLoS Med"},{"issue":"3","key":"R14-20260515","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2471\/BLT.10.084103","article-title":"Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea","volume":"89","author":"Davis","year":"2011","journal-title":"Bull World Health Organ"},{"issue":"1","key":"R15-20260515","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/ncomms6606","article-title":"Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis","volume":"5","author":"Okell","year":"2014","journal-title":"Nature Comm"},{"issue":"2","key":"R16-20260515","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4314\/ajid.v4i2.55145","article-title":"Is chloroquine better than artemisinin combination therapy as first-line treatment in adult Nigerians with uncomplicated malaria? A cost-effectiveness analysis","volume":"4","author":"Bello","year":"2010","journal-title":"Afr J Infect Dis"},{"key":"R19-20260515","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R20-20260515","doi-asserted-by":"crossref","first-page":"40-6","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"R21-20260515","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/XEB.0000000000000152","article-title":"The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI)","volume":"17","author":"Munn","year":"2019","journal-title":"Int J Evid Based Healthc"},{"key":"R22-20260515","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"R23-20260515","doi-asserted-by":"crossref","first-page":"1225-34","DOI":"10.1016\/j.jval.2023.04.004","article-title":"Developing Criteria for Health Economic Quality Evaluation tool","volume":"26","author":"Kim","year":"2023","journal-title":"Value Health"},{"key":"R24-20260515","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R25-20260515","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R26-20260515","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: a new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"R29-20260515","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2023.09.017","article-title":"Using PROGRESS-plus to identify current approaches to the collection and reporting of equity-relevant data: a scoping review","volume":"163","author":"Karran","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"R31-20260515","doi-asserted-by":"crossref","first-page":"140-50","DOI":"10.1016\/j.jclinepi.2012.04.012","article-title":"GRADE guidelines: considering resource use and rating the quality of economic evidence","volume":"66","author":"Brunetti","year":"2013","journal-title":"J Clin Epidemiol"}],"container-title":["JBI Evidence Synthesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-25-00243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:56:52Z","timestamp":1786453012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-25-00243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":25,"URL":"https:\/\/doi.org\/10.11124\/jbies-25-00243","relation":{},"ISSN":["2689-8381"],"issn-type":[{"value":"2689-8381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}